ClinicalTrials.gg
RecruitingNCT07211542Updated Apr 8, 2026

A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis

A Phase 2 interventional study of SHR-1905 Injection and SHR-1905 Injection Blank Preparation in Moderate-to-severe Atopic Dermatitis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. — 3 open to participants now, 5 under way, 2 of them phase 3. Dermatitis, Atopic · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
11th of 14
75 · median 159
Started
2025
with 1 other
Phase 2
6 of 14
1 open now
Registered
10th of 14
by date

Among the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., this one is the 11th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 2, and was the 10th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Dermatitis, Atopic by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

This trial was designed to evaluate the efficacy and safety of SHR-1905 in patients with moderate-to-severe atopic dermatitis.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The subjects have voluntarily signed the form prior to the start of any procedures related to the study, are able to communicate smoothly with the researcher, understand and are willing to strictly abide by the requirements of this clinical research protocol to complete the study.
  2. At the time of signing the informed consent, the subjects are ≥ 18 years old and ≤ 75 years old, male or female.
  3. Have atopic dermatitis at screening.

Exclusion criteria

Exclusion Criteria:

  1. to the study drug or any ingredient in the study drug.
  2. Have other active skin disease or skin complications due to other conditions that may affect the evaluation of Atopic Dermatitis (AD).
  3. Has or has a history of malignancy.
  4. Have serious concomitant diseases and other conditions that the investigator considers inappropriate to participate in this trial.
  5. Females who are pregnant or lactating.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    SHR-1905 Injection Group - Dose 1

    Dose 1.

    Drug: SHR-1905 Injection

  • Placebo comparator
    SHR-1905 Injection Placebo Group

    Drug: SHR-1905 Injection Blank Preparation

  • Experimental
    SHR-1905 Injection Group - Dose 2

    Dose 2.

    Drug: SHR-1905 Injection

Interventions

  • SHR-1905 injection.

  • DrugSHR-1905 Injection Blank Preparation

    SHR-1905 injection blank preparation.

06

What researchers measure

Primary outcomes

  1. The proportion of subjects whose Eczema Area and Severity Index (EASI) score decreased ≥ 75% compared to the baseline.

    Eczema Area and Severity Index (EASI) score using the Eczema Area and Severity Index scale.

    Time frame: Week 16.

Secondary outcomes

  1. The proportion of subjects with Investigator's Global Assessment (IGA) score of 0 or 1 (on a 0-4 scale) and a decrease of ≥2 points from the baseline.

    Investigator's Global Assessment (IGA) score using the Investigator Global Assessment (IGA) scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  2. The proportion of subjects whose Investigator's Global Assessment (IGA) score decreased ≥ 2 points compared to the baseline.

    Investigator's Global Assessment (IGA) score using the Investigator Global Assessment (IGA) scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  3. The change value of change in the Itch Numeric Rating Scale (Itch-NRS) score from the baseline.

    The Itch Numeric Rating Scale (Itch-NRS) score using the the Worst Itch Numeric Rating Scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  4. The percentage of change in the Itch Numeric Rating Scale (Itch-NRS) score from the baseline.

    The Itch Numeric Rating Scale (Itch-NRS) score using the the Worst Itch Numeric Rating Scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  5. The proportion of subjects whose EASI score decreased ≥ 75% compared to the baseline.

    EASI score using the EASI scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  6. The proportion of subjects whose EASI score decreased ≥ 90% compared to the baseline.

    EASI score using the EASI scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  7. The proportion of subjects whose EASI score decreased ≥ 50% compared to the baseline.

    EASI score using the EASI scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  8. The change value in EASI score from the baseline.

    EASI score using the EASI scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  9. The percentage of change in EASI score from the baseline.

    EASI score using the EASI scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  10. The change in Body Surface Area Involvement of Atopic Dermatitis (BSA) from the baseline.

    BSA score using the BSA scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  11. The percentage of change in Body Surface Area Involvement of Atopic Dermatitis (BSA) from the baseline.

    BSA score using the BSA scale.

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

  12. Adverse events (AEs).

    Time frame: At Day14、Day28、Day56、Day84、Day112、Day140、Day168、Day210、Day252.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2026, 10 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2025
First posted
Oct 8, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Feb 2027
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07211542
Responsible party
Sponsor
First posted
Oct 8, 2025
Start date
Nov 7, 2025
Primary completion
Sep 2026 (estimated)
Completion
Feb 2027 (estimated)
Last update
Apr 8, 2026

Study contacts

Ran Li
Contact
ran.li@hengrui.com
+86-0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SHR-1905

Start the discussion